MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

被引：0

作者：

Nastoupil, Loretta J.

Song, Yuqin

Sehn, Laurie Helen

Sarkozy, Clementine

Zinzani, Pier Luigi

Silvestre, Antonio Salar

Zhang, Jun

Huang, Sha

Wang, Julie

Delarue, Richard

Trotman, Judith

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Inst Curie, Paris, France

[5] Univ Bologna, Bologna, Italy

[6] Hosp del Mar, Barcelona, Spain

[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[8] BeiGene USA Inc, San Mateo, CA USA

[9] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[10] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7590

引用

页数：1